Morbimortalidad precoz y alejada del reemplazo valvular aórtico con prótesis mecánica y biológica durante la última década: El estándar de oro
| Autor: | Claudio Arretz V, Sergio Morán V, Ricardo Zalaquett, Ignacio Cifuentes, Rolando Rebolledo, Alejandro F. Ramírez, Pedro Becker, Manuel J Irarrázaval, Iván Godoy |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Prosthetic valve
medicine.medical_specialty business.industry Gold standard Retrospective cohort study General Medicine Perioperative medicine.disease Actuarial survival Surgery Thoracic surgery Aortic valve replacement Aortic valve surgery medicine Cardiovascular surgical procedures Aortic valve Young adult business |
| Zdroj: | Revista médica de Chile v.137 n.9 2009 SciELO Chile CONICYT Chile instacron:CONICYT |
| ISSN: | 0034-9887 |
| DOI: | 10.4067/s0034-98872009000900003 |
| Popis: | Background: There is a growing interest in alternative techniques for aortic valve replacement (AVR). Therefore it is important to have updated results of conventional AYR as a valid comparative standard. Aim: To evaluate both perioperative and ¡ate morbidity and mortality in patients undergoing conventional AVR, with either mechanical (RVAm) or biological (RVAb) prostheses. Patients and methods: Retrospective review of medical records and operative protocols of patients undergoing AVR between January 1995 and December 2005. Patients with previous cardiac surgery, aortic balloonplasty or simultaneous cardiovascular procedures were excluded. Results: During the study period, 788 patients underwent AVR and 317 met the inclusion criteria. Of the latter, 175patients aged 13 to 83years (63% males) were subjected to AVRm and 142patients aged 49 to 87 years (64% males), were subjected to AVRb. Five (1.6%) patients died during the perioperative period (one AVRm and four AVRb). All were older than 65years. Perioperative complications were recorded in 29 and 25% of patients in AVRm and AVRb groups, respectively (NS). During a median follow-up of six years, complications were recorded in 12 and 4% of patients in AVRm and AVRb groups, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|